The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene

T. Ogawa, M. Kusumoto, K. Mizumoto, E. Nagai, A. Ikubo, Y. Aoki, H. Niiyama, N. Sato, M. Tanaka

Research output: Contribution to journalArticle

Abstract

The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene in the treatment of cancer are described as follows. 1. Vector: The adenoviral vector is useful for immunogene therapy because of its high transduction ability and wide tissue tropism. 2. Safety: Adenovirus has a history of use in vaccines. 3. Efficacy for various cancers: Tumor vaccines could be used for various kinds of cancer cells. 4. Species differences: The problem is that there are no useful human cancer models of immunogene therapy. 5. Evaluation of the clinical protocol: Safety, not efficacy, should be evaluated in a phase 1 study. Since the effects of GM-CSF tumor vaccination on established tumors are unknown, our protocol could be applied to the prevention of local recurrence or metastasis after a relatively or absolutely curative operation.

Original languageEnglish
Pages (from-to)621-623
Number of pages3
JournalBiotherapy
Volume13
Issue number5
Publication statusPublished - Jun 26 1999

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Adenoviridae
Cancer Vaccines
Genes
Neoplasms
Therapeutics
Safety
Tropism
Clinical Protocols
Vaccination
Vaccines
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ogawa, T., Kusumoto, M., Mizumoto, K., Nagai, E., Ikubo, A., Aoki, Y., ... Tanaka, M. (1999). The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene. Biotherapy, 13(5), 621-623.

The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene. / Ogawa, T.; Kusumoto, M.; Mizumoto, K.; Nagai, E.; Ikubo, A.; Aoki, Y.; Niiyama, H.; Sato, N.; Tanaka, M.

In: Biotherapy, Vol. 13, No. 5, 26.06.1999, p. 621-623.

Research output: Contribution to journalArticle

Ogawa, T, Kusumoto, M, Mizumoto, K, Nagai, E, Ikubo, A, Aoki, Y, Niiyama, H, Sato, N & Tanaka, M 1999, 'The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene', Biotherapy, vol. 13, no. 5, pp. 621-623.
Ogawa, T. ; Kusumoto, M. ; Mizumoto, K. ; Nagai, E. ; Ikubo, A. ; Aoki, Y. ; Niiyama, H. ; Sato, N. ; Tanaka, M. / The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene. In: Biotherapy. 1999 ; Vol. 13, No. 5. pp. 621-623.
@article{ed7a047c173847748c5d20952a2130ab,
title = "The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene",
abstract = "The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene in the treatment of cancer are described as follows. 1. Vector: The adenoviral vector is useful for immunogene therapy because of its high transduction ability and wide tissue tropism. 2. Safety: Adenovirus has a history of use in vaccines. 3. Efficacy for various cancers: Tumor vaccines could be used for various kinds of cancer cells. 4. Species differences: The problem is that there are no useful human cancer models of immunogene therapy. 5. Evaluation of the clinical protocol: Safety, not efficacy, should be evaluated in a phase 1 study. Since the effects of GM-CSF tumor vaccination on established tumors are unknown, our protocol could be applied to the prevention of local recurrence or metastasis after a relatively or absolutely curative operation.",
author = "T. Ogawa and M. Kusumoto and K. Mizumoto and E. Nagai and A. Ikubo and Y. Aoki and H. Niiyama and N. Sato and M. Tanaka",
year = "1999",
month = "6",
day = "26",
language = "English",
volume = "13",
pages = "621--623",
journal = "Biotherapy",
issn = "0914-2223",
number = "5",

}

TY - JOUR

T1 - The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene

AU - Ogawa, T.

AU - Kusumoto, M.

AU - Mizumoto, K.

AU - Nagai, E.

AU - Ikubo, A.

AU - Aoki, Y.

AU - Niiyama, H.

AU - Sato, N.

AU - Tanaka, M.

PY - 1999/6/26

Y1 - 1999/6/26

N2 - The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene in the treatment of cancer are described as follows. 1. Vector: The adenoviral vector is useful for immunogene therapy because of its high transduction ability and wide tissue tropism. 2. Safety: Adenovirus has a history of use in vaccines. 3. Efficacy for various cancers: Tumor vaccines could be used for various kinds of cancer cells. 4. Species differences: The problem is that there are no useful human cancer models of immunogene therapy. 5. Evaluation of the clinical protocol: Safety, not efficacy, should be evaluated in a phase 1 study. Since the effects of GM-CSF tumor vaccination on established tumors are unknown, our protocol could be applied to the prevention of local recurrence or metastasis after a relatively or absolutely curative operation.

AB - The benefits and problems associated with clinical application of immunogene therapy with adenovirus harboring the GM-CSF gene in the treatment of cancer are described as follows. 1. Vector: The adenoviral vector is useful for immunogene therapy because of its high transduction ability and wide tissue tropism. 2. Safety: Adenovirus has a history of use in vaccines. 3. Efficacy for various cancers: Tumor vaccines could be used for various kinds of cancer cells. 4. Species differences: The problem is that there are no useful human cancer models of immunogene therapy. 5. Evaluation of the clinical protocol: Safety, not efficacy, should be evaluated in a phase 1 study. Since the effects of GM-CSF tumor vaccination on established tumors are unknown, our protocol could be applied to the prevention of local recurrence or metastasis after a relatively or absolutely curative operation.

UR - http://www.scopus.com/inward/record.url?scp=0033029052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033029052&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033029052

VL - 13

SP - 621

EP - 623

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 5

ER -